Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week

Table 4 Individual RTV plasma concentrations in patients treated with RBT 150 mg TPW or RBT 300 mg TPW

Patients	Sex	Age (years)	Weight (kg)	C₀ (µg/mL)	C₁	C₂	C₃	C₄	C₆	C₈	C₁₂	AUC_0–12 (µg h/mL)	Cl(L/h/kg)	C_max	T_max
First group (RBT 150 mg TPW)
Patient1	F	39	50.5	1.2	0.4	1.7	0.64	1.28	0.7	2.4	0.2	7.8	0.25	1.28	4
Patient3	M	36	56.8	2.1	1.86	2.5	0.4	0.5	1	1	1.33	8.9	0.19	1.86	1
Patient5	M	43	45.2	1.43	2	2.24	1.81	2.26	1.42	1.5	1.7	12.8	0.17	2.26	4
Patient7	M	32	44	2.1	1.56	1.56	1.26	1.3	2.74	1.91	1.7	12.2	0.18	2.74	6
Patient9	F	39	36	2.96	2.5	2.87	3.16	2.74	2.42	1.93	2.84	18.5	0.15	3.16	3
Patient11	F	33	57.6	7.5	8	10.3	10.8	11.5	10.7	8.2	8.3	67.4	0.03	11.5	4
Patient13	M	34	55	1.85	1.91	1.72	1.65	1.2	1.64	1.24	1.1	10.8	0.17	1.91	1
Patient15	M	24	52	4.11	3.8	3.6	3.5	2.7	3.3	2.8	3.6	23.5	0.08	3.6	2
Patient17	M	47	60	3.1	3.1	2.6	2.9	1.7	1.5	1.2	0.6	14.8	0.11	2.9	3
Second group (RBT 300 mg TPW)
Patient2	F	33	40	Low	Low	1	1.33	1.44	1.22	1.1	0.62	6.4	0.39	1.44	4
Patient4	M	44	55	0.41	0.37	0.4	0.3	0.38	0.3	0.28	low	2.2	0.81	0.4	2
Patient6	F	33	40.1	0.2	Low	0.8	0.8	0.9	0.8	0.9	0.6	4.6	0.54	0.9	4
Patient8	M	32	60.8	2.72	1.97	2.22	1.41	0.95	1.45	0.66	0.53	10.3	0.16	2.22	2
Patient10	F	32	40.2	1.84	2.14	2.43	2.4	1.67	1.3	1	0.7	12.2	0.20	2.43	2
Patient12	F	25	49.2	1.55	1.64	1.9	1.9	2	2.5	2	1.86	13.6	0.15	2.5	6
Patient14	F	44	52	2.3	1.5	1.12	1.2	1	0.5	0.13	Low	6.6	0.29	1.5	1

RBT rifabutin, TPW three times per week, LPV lopinavir, RTV ritonavir, Cn drug plasma concentration at the specified time, C_max maximum (peak) plasma drug concentration, T_max time to reach maximum (peak) plasma concentration following drug administration, C0 plasma drug concentration before the morning dose, C12 plasma drug concentration before the evening dose (12 h post-dose)

ISSN: 1476-0711